Navigating the future-scape of pharmaceutical medicine

FPM Annual Symposium | 22 November 2023

Faculty of
Pharmaceutical
Medicine

MEET OUR PARTNERS

SILVER PARTNERS

Drug Safety Research Unit DSRU

The Drug Safety Research Unit (DSRU) is the UK's leading pharmacovigilance and pharmacoepidemiology unit, which is internationally renowned for designing and conducting observational studies with pharma companies in the UK and EU, including post-authorisation studies and risk minimisation activities. As a leading provider of pharmacovigilance training, the DSRU also provides FPM-accredited courses in pharmacovigilance, risk-benefit assessment and pharmacoepidemiology, which support PMST.
dsru.org

MyMedical DEPARTMENT

My Medical Department is a physician-led medical consultancy, offering a broad range of industry services, where, how and when you need us. Led by industry experts including two board-certified pharmaceutical physicians, our multi-disciplinary team of experts deliver on-demand medical department functions tailored to your organisation's specific needs.
mymedicaldepartment.com/

PHARMA PARTNERS

Pharma-Partners has one of the most comprehensive specialist networks in the Life Science industry, we are continually expanding through market mapping and referrals. This, combined with our unrivalled network, sector knowledge, and years of experience, has cemented our reputation as one of the leading life sciences recruitment agencies.
pharma-partners.net

BRONZE PARTNERS

BioLuminux

Bioluminux Clinical Research is a network of dedicated Investigator sites in the UK and United States with focus on late phase clinical trial studies. With offices in Milton Keynes UK, Naperville-Illinois and Princeton, New Jersey, we offer clinical trial solutions to provide innovative and quality research to clinical trial participants.
www.bioluminux.com

WELCOME

Faculty of Pharmaceutical Medicine

Welcome to the 2023 FPM Annual Symposium – Navigating the future-scape of pharmaceutical medicine. We're delighted to be back in the inspiring environment of the Wellcome Collection, as well as welcoming a global audience online.

This is an exciting time for our specialty. We are seeing pharmaceutical physicians around the world leading rapid scientific innovation and disruption in fields such as artificial intelligence, genomics and advanced therapies, which are revolutionising medical research and practice.

FPM and our members continue to work tirelessly to provide the foundations for this innovation – strengthening standards in the discipline and collaborating to grow our influence and voice. We are also engaging with patients and diverse communities around the world and supporting them to influence policy and practice.

This year's symposium will address some of the biggest challenges and the most exciting opportunities facing global healthcare. As countries and healthcare systems strive to recover from COVID-19, the lessons the pandemic taught are being infused into a new pioneering and collaborative spirit.

Today we'll discuss how we should harness scientific innovations, we'll debate cultural and societal expectations in relation to pharmaceutical medicine, and we'll reflect on the current national and global policy climate. The themes will be varied, but all tied together by the threads of innovation, disruption, and equity.

Thank you for attending today and we hope you enjoy the Annual Symposium 2023! Remember, if you miss any sessions from the main auditorium or would like to revisit key moments in the symposium, delegates will have complimentary access to these sessions via the FPM On Demand platform from early December.

Dr Flic Gabbay
FPM President
Dr Marcia Philbin
FPM Chief Executive
Dr Karen Mullen
Chair of the 2023 Annual Symposium

PROGRAMME

08:40 - 09:20 **ARRIVAL Registration and Breakfast**

09:20 - 09:30 **WELCOME**

Welcome by Dr Flic Gabbay FFPM (President, FPM)
Housekeeping and overview of themes by Dr Karen Mullen FFPM (event chair)

09:30 - 10:10 **CONVERSATION**

Life sciences innovation, impact on public health and the role of pharmaceutical medicine

Prof Kevin Fenton CBE (President of the Faculty of Public Health and the Regional Director for London in the Office for Health Improvement and Disparities (OHID))
Sir Jonathan Symonds CBE (Chair of the Board of GSK, Non-Executive Director, Genomics England Limited, UK Life Science Champion)
Moderator: Dr Flic Gabbay (President, FPM)

Pharmaceutical medicine is at the heart of research and development in the United Kingdom. According to Life Sciences Minister George Freeman earlier this year, the higher education sector in the UK accounted for some £2.2 billion of R&D in the medical and health sciences, or 0.10% of GDP. The UK's business sector, meanwhile, in 2020 accounted for some £5 billion of pharmaceutical R&D, the latest in a several year upwards trend. In this session, our panellists discuss how this upward trajectory can be maintained in the future as the route from innovation to implementation becomes ever faster.

10:10 - 10:50 **KEYNOTE**

Zero to AI

Dr Trishan Panch (President, Harvard TH Chan School of Public Health Alumni Association)

This session takes the audience from "Zero to AI" by cultivating a first principles understanding of software engineering, machine learning, deep learning, and ultimately, generative AI.

The material is closely aligned with and inspired by the well-received "Applied AI in Healthcare" course that Dr Trishan Panch teaches at the Harvard TH Chan School of Public Health. It is designed to set the scene for the other talks and interactive sessions to follow.

10:50 - 11:20 **COFFEE, NETWORKING AND EXHIBITION**
Meet our event partners

11:20 - 12:30 **BREAKOUTS** Your choice of:

Global Health: An end-to-end opportunity to drive health equity

Sameer Sawarkar (Co-Founder & CEO – Neurosynaptic Communications Pvt. Ltd.) [online]
Dr Craig Tipple (Medical Director at DnDI)
Dr Juliet Addo (Academic Engagement Director, Global Health & Head of the Africa Open Lab at GSK)
Chair: Dr Pauline Williams FFPM (Independent Consultant in Global Health and Translational Medicine)

Join this breakout session to hear about novel approaches to accelerate medicines R&D and access in low resource settings. Speakers from different sectors will discuss the challenges and opportunities in developing and delivering health innovations to patients worldwide, with examples of open-innovation capacity-building, delivering clinical trials in neglected diseases and the use of technology to provide healthcare in remote areas. Gain insights into how you can promote health equity in your own role in pharmaceutical medicine.

Decoding genomics: promise and perils for pharmaceutical physicians

Prof Frances Flinter (Emeritus Professor of Clinical Genetics)
Parker Moss (Chief Ecosystems and Partnership Officer)
Chair: Dr Jeymi Tambiah MFPM(Dis) (Senior Vice President, Clinical Development and External Innovation, Biosplice Therapeutics, San Diego)

Join this breakout svession to explore the exciting potential of genomics technology applications in clinical medicine, drug development and their potential for impact on pharmaceutical medical practice. Listen to our speakers from Genomics England and The Nuffield Council on Bioethics discuss how genomics can change the trajectory of medicine towards greater personalised and precision-based care. What are examples of the successes, the challenges and the ethical concerns we may be facing as we step into the future?

How to leverage Artificial Intelligence in Pharmaceutical Medicine: Practical Examples in the Real World

Are you clear how you can make the most of the AI/ML revolution?

Dr Trishan Panch (President, Harvard TH Chan School of Public Health Alumni Association)
Dr Rav Seeruthun (Chief Medical Officer and co-founder of health-equity.ai)
Chair: Dr Andrew Bate (VP & Head, Safety Innovation & Analytics, GSK)

Our workshop will expose you to real-world scenarios where AI has been implemented, and what's next.
1. Join us to learn how AI can transform the R&D process in the life sciences and beyond
2. Discover how AI can help solve health inequalities and improve access to care for underserved populations
3. Hear how AI can augment and enhance Medical Safety's traditional approaches
4. Let us then all discuss the practicalities of AI implementation in the industry

12:30 - 13:40 **LUNCH AND NETWORKING**

Lunch, partners exhibition, and networking

13:40 - 14:30 **PLENARY PANEL**

Climate, health and equity: a business critical and patient centric opportunity for industry leadership

Dr Emma Iovoli MFPM (Life Sciences Consultant – Climate and Health)
Dr Alan Dangour (Director of Climate and Health, Wellcome Trust)
Dr Ashton Harper (Head of Medical Affairs, UK and Ireland, Roche Diagnostics)
Dr Fiona Adshead (Chair, Sustainable Healthcare Coalition)
Chair: Dr Pauline Williams FFPM (Independent Consultant in Global Health and Translational Medicine)

This session will explore business critical and patient centric opportunities emerging from the rapid transition to sustainable healthcare globally and in the UK. After inspiring keynote presentations, an expert panel will be convened to discuss why climate and health is relevant for pharmaceutical physicians and the potential for improving patient outcomes through integrating climate and health actions.

14:40 - 15:30 **BREAKOUTS** Your choice of:

Pharma's Paradigm Shift: Harnessing the Power of Patient Innovators and Disrupters for Healthcare Transformation

Seb Tucknott (Founder and CEO of IBDrelief)
Clare Campbell-Cooper (Global Head of Digital Health and Innovation at Fortrea)
Dr Rich Gorman (Research Fellow at Brighton and Sussex Medical School)
Graeme Johnston (Founder member and current Board and Executive Committee member of Patient Focused Medicines Development (PFMD))
Chair: Dr Liz Clark (Visiting Lecturer and Patient Engagement Theme Lead at the Centre for Pharmaceutical Medicines Research)

Hear first-hand from our panel of experienced patient advocates who have personally contributed to scientific innovation through collaboration with pharma and other stakeholders. Gain valuable insights into the transformative impact of having a patient on your team. Get their ideas on how you can work with them share their passion, wisdom and experience to enhance projects, products and initiatives and see how collaboration paves the way for more effective, ethical and patient-focused solutions.

Accelerated Access to Medicines – Regulatory and Reimbursement

Rachel Cummings (Principal Consultant at Decisive Consulting)
Dr Julie Warner (Vice President, Regulatory Affairs at Boyds)
Chair: Dr Kirsty Wydenbach (Head of Regulatory Strategy at Weatherden)

Getting medicines to patients can be a bumpy road. Regulators offer multiple pathways for accelerating timelines and approvals to smooth that path, but it doesn't stop there – reimbursement and HTA acceptance often prove to be further barriers. The panel will discuss the early routes for access you may wish to consider, including some top tips for success. Then be ready with your questions as we also delve into the EU Regulation on Health Technology Assessment and what its application in January 2025 means for you.

A different future: communicating about medicines safety within promotion

Dr Alison Cave (Chief Safety Officer, MHRA)
Dr Amit Aggarwal (Executive Director for Medical Affairs at the ABPI)
Chair: Dr Nick Broughton (Educator and Founding Partner, Ethos Pharmaceutical Ethics and Compliance Ltd.)

How many hours of your life have you spent reviewing and discussing efficacy messaging? And how many discussing safety messaging? Have you ever been to a brand team

meeting where the only topic was what to communicate to health professionals about a medicine's safety profile (when there wasn't some sort of crisis). Isn't it time we took safety communication seriously and dispensed with bland nonsense like 'generally well tolerated'? Is it time we just thought about it more? Multiple recent ABPI Code cases would suggest it is. Join us as we get three different perspectives on what good communication about medicines safety is.

15:30 - 15:50 **TEA AND EXHIBITION Meet our event partners**

15:50 - 15:55 **PARTNER SPOTLIGHT My Medical Department**

15:55 - 16:00 **Formula for the future**
Dr Marcia Philbin (FPM, Chief Executive)

16:00 - 16:55 **PLENARY PANEL**
How can the UK life sciences ecosystem work to encourage drug development and enable access?
Dr David Jefferys FFPM (Senior Vice President, Eisai)
Dr June Raine DBE FFPM (CEO of the Medicines and Healthcare products Regulatory Agency)
Prof Andrew Farmer (Director, NIHR HTA Programme)
Moderator: Prof Alan Boyd FFPM (CEO of Boyds)

In 2021 the UK Government published its Life Sciences Vision to focus on what Government, the NHS, Regulators, Companies & Medical Charities must do to allow the pharmaceutical industry to grow and succeed in the UK, thereby bringing real benefits for patients. During this panel session we will discuss what progress has been made and are the objectives of the vision being achieved.

16:55 - 17:00 **CLOSING REMARKS**
Dr Flic Gabbay PFPM (President, FPM)

17:00 - 18:00 **DRINKS RECEPTION AND NETWORKING**

Professor Kevin Fenton CBE PrFPH PhD FRCP

President of the Faculty of Public Health and the Regional Director for London in the Office for Health Improvement and Disparities

Kevin, President of the Faculty of Public Health, is a senior public health expert and infectious disease epidemiologist. He holds leadership roles in public health across the UK and globally. His interests include health inequalities, infectious disease control, climate justice, and urban health. As the Regional Director for London at the Office for Health Improvement and Disparities, he advises the Mayor of London and NHS London. He is the UK government's Chief Advisor on HIV and chairs the HIV Action Plan Implementation Steering Group. In his role, he collaborates with various stakeholders, including the Academy of Royal Medical Colleges and the UK Local Government Association, emphasising global and UK-wide cooperation.

Sir Jonathan Symonds CBE



Chairman of the Board of GSK

Jon has extensive international financial, life sciences and governance experience.

He served as an Independent Non-Executive Director of HSBC Holdings plc from April 2014, and as Deputy Group Chairman from August 2018, until his retirement from the Board in February 2020. He was previously Chairman of HSBC Bank plc, Chief Financial Officer of Novartis AG, Partner and Managing Director of Goldman Sachs, Chief Financial Officer of AstraZeneca plc, and a Partner at KPMG. His governance experience includes roles as Non-Executive Director and Chair of the Audit Committees of Diageo plc and QinetiQ Group plc, Non-Executive Chair of Proteus Digital Health Inc and Non-Executive Director of Rubius Therapeutics, Inc.

Jon is a Fellow of the Institute of Chartered Accountants in England and Wales.

Dr Trishan Panch MD MPH

President, Harvard TH Chan School of Public Health Alumni Association

Trishan, an entrepreneur, physician, and keynote speaker, currently serves as CEO of LUNR, Board Director at Lumin, and President of the Harvard TH Chan School of Public Health Alumni Association. He's also the Board Chair at Healthcare for All. Trishan co-founded Wellframe, where he held multiple roles and patented its technology. He received Harvard's Public Health Innovation Award for his digital health contributions. As an Instructor at Harvard TH Chan School of Public Health, he founded the AI for Health Care specialisation program. Trishan is an esteemed keynote speaker, addressing healthcare providers, governments, consultancies, and technology organisations, drawing on 17 years of medical practice and leadership in London's underserved communities. He advises Boston Children's Hospital through its Innovation Advisory Board.

Dr Juliet Addo

Academic Engagement Director, Global Health & Head of the Africa Open Lab at GSK

Juliet is the Academic Engagement Director of Global Health and Head of the Africa Open Lab at GSK. She fosters research and academic partnerships, focusing on strengthening the capabilities of young African scientists. Juliet, who holds a PhD in Epidemiology from LSHTM, advocates for African-led solutions to health challenges and encourages the continent's leadership in scientific research. She graduated from the University of Ghana Medical School and practised as a clinician in Ghana. Juliet also earned an MSc in Public Health from the University of Ghana School of Public Health. She is a Fellow of the UK Higher Education Academy and an honorary Assistant Professor of Epidemiology at LSHTM. Juliet lectured in epidemiology at LSHTM before joining GSK in 2016.

Sameer Sawarkar

Co-Founder & CEO – Neurosynaptic Communications Pvt. Ltd.

Sameer's primary work is in affordable technologies for Rural Healthcare. Neurosynaptic's completely indigenous ReMeDi® platform has proudly enabled over 2800 Rural Digital Health centres, bringing healthcare access to over 54 Mn population in India. ReMeDi® is also deployed in twelve other countries in Africa, SE Asia and Latin America. Neurosynaptic does pioneering work in medical devices and software. He is an Ashoka Fellow. His achievements include Engineering Awards, Patents, and Publications. Under his leadership, Neurosynaptic has received several recognitions, including the "Global Indus Technovator Award" from MIT, Boston, "Technology Pioneer" by the World Economic Forum, Switzerland and selected amongst "Global Top 100 Innovative Companies" by Red Herring. He is an alumnus of IISc, Bangalore.

Dr Pauline Williams CBE FMedSci FFPM

Independent Consultant in Global Health and Translational Medicine

With over 30 years of pharmaceutical physician experience and a background in Translational Medicine, Pauline served as Head of Global Health R&D at GSK. Her focus was addressing global health challenges through drug discovery, capacity-building, and innovative access models. Under her leadership, Umbipro and Kozenis gained regulatory approval for low-resource settings. Pauline also established open-innovation partnerships in TB, maternal and child health, and non-communicable diseases. After retiring from GSK and the MRC Council, she now dedicates her time to pro bono work in Global Health, offering consultancy, mentoring, and advocating for R&D in underserved areas.

Dr Craig Tipple MRCP

Medical Director (CMO), Drugs for Neglected Diseases initiative

Craig is the Medical Director (CMO) at the Drugs for Neglected Diseases initiative, an international non-profit organisation that collaborates to develop medicines for neglected diseases and populations. He holds a background in infectious disease with a PhD from Imperial College London, membership in the Royal College of Physicians, and post-grad qualifications in HIV, Genitourinary Medicine, and human pharmacology. Craig gained drug development experience at GSK, focusing on antibiotics and treatments for hepatitis B and viral diseases. In various roles, including Medical Director of GSK's Phase I trials unit and discovery medicine director, he supported early phase and translational medicine projects. Most recently, he served as the Clinical Development Lead for the GSK/Vir COVID mAb treatment, sotrovimab.

Professor Frances Flinter

Emeritus Professor of Clinical Genetics

Frances is the Emeritus Professor of Clinical Genetics and former Caldicott Guardian at Guy's & St Thomas' NHS Foundation Trust, a member of the Nuffield Council on Bioethics and a Member of the Human Fertilisation and Embryology Authority. She was previously a Scientific Advisor to the Science and Technology Committee for their investigation into Direct-to-Consumer genetic tests and is a former President of the Clinical Genetics Society. Clinically, her special interests include inherited renal diseases, pre-implantation genetic testing and genetic testing in children.

Parker Moss

Chief Partnerships Officer, Cancer Lead, Genomics England

Parker manages Genomics England's strategic partnerships in biopharma, NHS, and academia. He co-leads the GEL cancer research program and oversees the bioinformatics tech program for global research access. Prior to that, he was part of Owkin's executive team in AI/ML cancer research. He served as an entrepreneur in residence at F-Prime and Eight Roads, focusing on life sciences tech investments. Parker held CTO roles in the NHS and non-executive positions, including the UK Health Minister's tech board and Cancer Research UK's Horizon board. He studied Physics and Philosophy at Durham University and resides in London with his family and dog, Duke. Beyond work, he's passionate about classical music.

Dr Jeymi Tambiah MBChB FRCS MS FAPCR MFPM(Dis)

Senior Vice President, Clinical Development and External Innovation, Biosplice Therapeutics, San Diego

Jeymi is a pharmaceutical physician with expertise in medical affairs, clinical development, and translational medicine. He currently serves as Senior Vice President of Clinical Development and External Innovation at Biosplice Therapeutics in San Diego, a biotech company focusing on mRNA splicing modulation in oncology, arthritis, and neurodegenerative diseases. Jeymi earned his medical qualifications from the Universities of St. Andrews and Manchester and completed a doctorate in immunology as a Wellcome Research Fellow at Imperial College. Before transitioning to the pharmaceutical industry, he worked as a specialist registrar in cardiothoracic surgery at Guys and St. Thomas' Hospitals in London.

Dr Rav Seeruthun FFPM

Chief Medical Officer and co-founder of health-equity.ai.

Rav is a Co-founder of Health-equity.ai, a company that uses AI to help solve health inequalities. Previous to this, he was an Officer and Vice-President at Genentech based in San Francisco. He moved to this role after four years as Country Medical Director of Roche UK. Rav studied medicine at St Mary's Hospital Medical School at Imperial College, London and practised for eight years in the NHS before joining the pharmaceutical industry in 2007. He is a fellow of the Faculty of Pharmaceutical Medicine and a William Pitt Fellow at Pembroke College, Cambridge, and he holds an executive MBA from Judge Business School, Cambridge.

Andrew Bate PhD

VP & Head, Safety Innovation & Analytics, GSK

Andrew, Vice President and Head of Safety Innovation and Analytics at GSK, is a key figure in enhancing safety capabilities as part of the Global Safety Leadership team. Previously, he was part of Pfizer's Global Epidemiology Leadership team and led the Research function at the Uppsala Monitoring Centre. Andrew earned a Master's in Chemistry from Oxford and a PhD in Clinical Pharmacology from Umea University, focusing on Machine Learning in pharmacovigilance. He held academic positions at Brunel University, NYU Grossman School of Medicine, and the London School of Hygiene and Tropical Medicine. Andrew boasts 100+ peer-reviewed AI-related publications and edited a journal issue on AI in Drug Safety. His book, "Evidence-Based Pharmacovigilance: Clinical and Quantitative Aspects," was published in 2018.

Dr Emma Lovoli MBChB MRCP UK MSc Dip Pharm Med MFPM

Life Sciences Consultant

Emma is a medical doctor and clinical academic with over a decade of experience within the pharmaceutical industry. She has worked as a doctor in the NHS in the UK, completed a Medical Research Council-funded PhD in respiratory disease, and has senior leadership experience in global and regional medical affairs, most recently as the Medical Head of Global Health at GSK. Emma is a strategic problem solver and visionary systems thinker, passionate about integrating climate and health strategies within the pharmaceutical business. Her focus is on helping medical affairs individuals and teams realise their opportunity to take patient and business-focused actions that drive co-benefits in climate and health.

Dr Alan Dangour

Director, Climate & Health – Wellcome Trust

In January 2022, Alan joined the Wellcome Trust to lead its ambitious new strategy to put health at the heart of global climate change action. Alan was previously based at the London School of Hygiene & Tropical Medicine for twenty years, where he was a Professor of Food and Nutrition for Global Health and Director of the Centre on Climate Change and Planetary Health. Alan led an interdisciplinary team working on the interconnections between environmental change, food systems and health. Familiar with working in national and international fora, Alan was an Expert Advisor to the Environmental Audit Committee of the UK Parliament and a Senior Research Fellow at the UK Department for International Development.

Dr Fiona Adshead

Chair, Sustainable Healthcare Coalition

Fiona leads the Sustainable Healthcare Coalition, promoting sustainable healthcare partnerships and action. She serves as an expert advisor and board member for global organisations on well-being and sustainability. With a prominent background in well-being and public health leadership, she reshapes thinking and develops innovative strategies in both business and government. Past roles encompass Deputy Chief Medical Officer, Director General in the UK Government, and positions at the World Health Organization and Bupa. Fiona holds a Visiting Professorship at UCL and Senior Associate status at the Cambridge Institute for Sustainability Leadership. Her recent board memberships include British Land's Sustainability Advisory Panel, Marks and Spencer's Sustainable Retail Advisory Board, and Business in the Community's Wellbeing Leadership Team.

Dr Ashton Harper

Head of Medical Affairs for Roche Diagnostics UK & Ireland

Ashton is Head of Medical Affairs for Roche Diagnostics UK and Ireland, where he leads a team responsible for clinical research across oncology, cardiology, neurology, infectious diseases, critical care, and women's health. He holds an MBBS and a B.Sc. in physiology and pharmacology from University College London. He trained as a gastrointestinal surgeon in the NHS, achieving membership in the Royal College of Surgeons. During his career, he has initiated numerous interventional clinical trials in a range of therapeutic areas, lectured across the globe, and published in surgery, gastroenterology, neurology, infectious diseases, and microbiology.

Seb Tucknott

Founder and CEO of IBDrelief

Seb has lived with the long-term chronic condition ulcerative colitis (UC) since 2008. He has used his experience as a patient and a web agency founder to create IBDrelief, a for-purpose company empowering people living with inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. He is passionate about improving the quality of life for patients living with long-term conditions through better education and improved support to self-manage their condition. He constantly seeks solutions to big healthcare problems to empower patients and place them at the heart of his work. Seb is an experienced patient, advocate, entrepreneur and speaker.

Clare Campbell-Cooper

Global Head of Digital Health and Innovation at Fortrea

Clare has over 25 years of experience, including 10+ years of senior management capacity. She has held management positions in Data Management, Phase I Operations, Strategy and Planning, Project Management and Global Project Delivery. She is now the Global Head of Digital Health and Innovation at Fortrea, where she is helping change the face of how clinical research develops. During COVID, Clare's husband died from glioblastoma, and her special interest lies in the relationship between the caregiver and the physician team and how digital technology can augment this.

Dr Richard Gorman

Research Fellow at Brighton and Sussex Medical School

Richard lives with haemophilia and is an active advocate within the rare disease community, where his work has focussed on expanding the opportunities for patient voices to shape healthcare. Additionally, Richard is a research fellow at Brighton and Sussex Medical School in the UK, where his work focuses on bringing lived experience into conversation with medical knowledge and practices to improve care. Prior research at the University of Exeter has also explored how to actively involve people affected by health conditions in laboratory research and support conversations that might involve sensitive topics like animal research.

Graeme Johnston

Founder member and current Board and Executive Committee member of Patient Focused Medicines Development (PFMD)

Graeme, a law graduate and former partner at PWC, has battled Rheumatoid Arthritis (RA) for nearly 20 years, forcing an early retirement in 2009. He chaired the National Rheumatoid Arthritis Society for six years, followed by involvement with pharmaceutical companies as a patient advocate and member of scientific advisory boards. In 2013, he joined a meeting of Big Pharma medical affairs professionals to enhance patient engagement. This led to the inception of PFMD (patientfocusedmedicine.org), a pioneering organisation focused on tools to bolster patient engagement for a decade. Graeme's commitment extends to serving as an NHS board member, chair of the local GP's PPG, and a public partner on an ARC.

Dr Liz Clark MBBS MSc FFPM FCMI FInstLM

Visiting Lecturer and Patient Engagement Theme Lead at the Centre for Pharmaceutical Medicines Research

Liz is an independent pharmaceutical physician and Visiting Lecturer at the Centre for Pharmaceutical Medicines Research within the Institute of Pharmaceutical Science at King's College London. With a background in clinical medicine and 28 years in pharma, her career has spanned various roles, primarily in Medical Affairs and most recently in Patient Engagement. She left her role as Vice-President of Medical Affairs at Norgine in 2021 and now works independently at KCL, in patient engagement consultancy, training, coaching, and in the Faculty of Pharmaceutical Medicine. Liz's patient engagement efforts earned her recognition as a finalist as a 'Champion for Patient Engagement' at the 2021 WEGO Awards. She's also establishing a forum at FPM for collaborative work with patients and communities.

Dr Julie Warner

Vice President, Regulatory Affairs at Boyds

Julie provides strategic advice to companies from discovery to registration. With over 20 years of experience, she specialises in developing regulatory strategies for advanced therapies and orphan and paediatric drugs. Julie started her career at Gregory Fryer Associates before taking on positions of increasing responsibility at Genzyme Europe Research, Clovis Oncology UK, and Roche. She joined Boyds to grow and lead its award-winning regulatory team, which specialises in developing advanced therapies (gene and cell- and tissue-based) for conditions including inherited diseases, oncology, and neurological and metabolic diseases. Julie is a TOPRA Fellow and was a finalist in the 2018 TOPRA Awards.

Rachel Cummings

Principal Consultant at Decisive Consulting

Rachel is a Principal Consultant at Decisive Consulting, a global market access consultancy. Rachel has over 20 years of experience in the life sciences industry. She started her career in medical publishing before moving into pharmaceutical companies. Over the last 14 years, Rachel has worked within several pharmaceutical companies, holding local, regional and global market access positions. Rachel has extensive experience planning for and submitting evidence to HTA bodies and developing and implementing global pricing, HEOR, RWE and access strategies. Rachel has a BA and an MA in Pure and Applied Biology from the University of Oxford, an MSc in Health Economics from LSE, and a PG Diploma in International Health Technology Assessment from ScHARR, University of Sheffield.

Dr Kirsty Wydenbach MFPM

Head of Regulatory Strategy at Weatherden

Kirsty, Head of Regulatory Strategy at Weatherden, brings over 13 years of experience as a medical assessor at the MHRA, focusing on ATMPs and first-in-human studies. She has significantly contributed to UK clinical trial regulation and EU CTR discussions, co-chairing a safety sub-group and serving as an EMA expert. Kirsty's collaborative regulatory efforts extend to the FDA, ACCESS consortium, and ICMRA. She has expertise in adaptive and novel trial designs, leading MHRA's efforts on novel trial designs for the LSIS and the MHRA ILAP. Additionally, she played a pivotal role in MHRA's COVID-19 clinical trials and provided expertise for vaccines in MHRA and the GVT.

Dr Amit Aggarwal MFPM

Executive Director for Medical Affairs at the ABPI

Amit, with 14+ years of pharmaceutical industry experience, was the UK and Ireland Medical Director at LEO Pharma. Previously, he spent a decade at Bayer, handling roles in pharmacovigilance global medical affairs, and later, as Director of Medical Affairs UK for General Medicine. He has a clinical background, having worked for 5 years in the NHS. Amit led product launches across various therapy areas such as oncology, women's health, cardiovascular medicine, dermatology, and thrombosis in the UK and globally. His education includes an MA in Neuroscience from the University of Cambridge and an MBBS from Guy's, King's & St Thomas' School of Medicine.

Dr Alison Cave

Chief Safety Officer, Medicines and Healthcare products Regulatory Agency

Alison joined the Medicines and Healthcare products Regulatory Agency (MHRA) in July 2021 as the Chief Safety Officer with responsibility for the safety of medicines and devices in the UK. She holds a BSc Honours degree and PhD from the University of London and has significant academic research and regulatory experience, the latter at both the European Medicines Agency (EMA) and MHRA. Previously she was Head of Cellular, Developmental and Physiological Sciences at the Wellcome Trust and most recently an Industrial Strategy Challenge Fund Director at UK Research and Innovation.

Dr Nick Broughton MFPM

Educator and Founding Partner, Ethos Pharmaceutical Ethics and Compliance Ltd.

Nick is a Founding Partner of Ethos, a company specialising in education and behaviour change in the field of pharmaceutical ethics and compliance. He is a pharmaceutical physician with over 20 years of experience within the industry, including senior medical roles in UK and European Medical and Regulatory Affairs for AstraZeneca and Celgene. He is actively involved in advising large and small pharmaceutical companies on their promotional and other activities across both traditional and digital channels. Nick has postgraduate qualifications in medical ethics and law from Keele University, UK. The educational programmes he has developed draw heavily on theories of medical ethics and their practical application in business decision-making and commercial campaigns.

Dr June Raine DBE FFPM

CEO of the Medicines and Healthcare products Regulatory Agency

June is CEO of the Medicines and Healthcare products Regulatory Agency. She trained in medicine in Oxford after completing a Master's degree research in Pharmacology. Her interest in drug safety led to a career in medicines regulation, which has spanned a number of roles in assessment, management and strategic development within the UK national authority. She was elected 2012 as the first chair of the European Pharmacovigilance Risk Assessment Committee and co-chair of the WHO Advisory Committee on the Safety of Medicinal Products. Her special interests are monitoring the outcomes of regulatory action, risk communication and patient involvement in the regulatory process.

Dr David Jefferys FFPM

Senior Vice President, Eisai

David is the Senior Vice President at Eisai and oversees global regulatory affairs, product development strategy, corporate affairs, government relations, and patient safety. With a strong clinical medicine and cardiology background, he has held distinguished roles including Director of Licensing and Executive Board Member at the MCA, CEO of the Medical Devices Agency, and acting CEO of MHRA. David co-founded ICH, served in leadership positions in organizations such as TOPRA and RAPS, and has a significant publication record in medicines, medical device regulation, and benefit-risk evaluation. Additionally, he is involved in various councils and boards related to pharmaceuticals and healthcare. He also holds the esteemed position of Junior Warden of the Society of Apothecaries of London.

Professor Andrew Farmer

Professor of General Practice, University of Oxford and Director, NIHR Health Technology Assessment Programme

Andrew leads a digital health technology research group at Oxford University Hospitals funded by the UK National Institute of Health Research (NIHR). He is also the Director of the NIHR Health Technology Assessment research funding program, where he commissions and oversees research that directly influences clinical practice and policy on tests, treatments, and therapies. Based at the University of Oxford's Nuffield Department of Primary Care Health Sciences, Andrew has also contributed to NICE Clinical Guidelines and held roles in NIHR research networks. In his current Director role, he promotes integrating clinical trials into practice while utilising clinical data effectively.

Dr Lisa Broad

Vice President and Head of Neurodegeneration Discovery, Lilly and Managing Director of Lilly Research Labs, UK

A physiologist/pharmacologist by training with 25 years research experience in academia and industry. Extensive drug discovery experience and knowledge ranging from target identification through to clinical proof of concept. 23 years' experience within the Neuroscience therapeutic area, developing symptomatic and disease modifying therapies for patients with chronic pain, migraine and neurodegenerative diseases. Partners closely with academics, charity partners and in private-public partnerships. Prior to joining Lilly, Lisa completed post-doctoral studies at the National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA and the University of Cambridge. Lisa received her doctorate from the University of Cambridge.

Professor Alan Boyd FRSB FFLM FRCP FFPM FMedSci

Past-President of FPM and CEO of Boyds

Alan, a prominent figure in pharmaceutical medicine, is the founder of Boyd Consultants Ltd, with expertise in medicines development. With biochemistry and medicine backgrounds, he held key roles at Glaxo, ICI, and Zeneca, eventually becoming the Global Head of Medical Research. Founding Ark Therapeutics and Boyds, he focuses on translating research into medications, bringing over 20 prescription products to market, including gene therapy treatments and a COVID-19 vaccine. Alan is an Honorary Professor at the University of Birmingham Medical School, received the 'Queens Award for Enterprise', and was honoured with a Fellowship from the AMS for his substantial contributions to medicine. He serves as a Non-Executive Director on three life-science company boards and is the ICT at the AMRC.

Dr Karen Mullen MBBS FRCP FFPM

Chair, FPM Annual Symposium 2023

Chief Medical Officer (CMO) & Vice President of Clinical and Medical Affairs, Boyds

With over two decades of pharmaceutical experience, Karen is an accomplished physician in drug development and medical affairs, having worked worldwide. Her expertise spans various therapy areas, including vaccines, cell and gene therapies, oncology, and rare diseases. Currently, Karen serves as the CMO and VP of Clinical and Medical Affairs at Boyds. Before joining Boyds, she held leadership positions, notably as the Country Medical Director UK at GlaxoSmithKline, overseeing a sizable medical department covering clinical research, pharma, and vaccines. Her roles at GSK included Head of Medical Affairs, Director of Vaccines, and Director of Metabolic Medicine. Karen has contributed to developing 20 medicines, encompassing vaccines, gene therapies, and monoclonal antibodies. She supervised the safety profiles of around 75 registered medicines.

FPM in Focus

Join our new mentoring platform

FPM Connect

Most of our members joined FPM for community engagement, to support their profession and for education, training, and career development. FPM Connect will support all these aspects, allowing a member who is looking for advice to connect directly with a member who would like to offer support. This new service is built using the popular PLD Mentoring Software platform which connects participants across geographical boundaries or specialties.

We need mentors! Our strength is you. Please help us to build and nurture our FPM community by putting yourself forward to be a mentor. With your support we can achieve even more for the benefit of the public. Please look out for emails with further information soon!

FPM Connect, the place where we can build and grow our community!

The DPM Training Programme 2024 is now open for bookings

If you plan to sit the Certificate or Diploma in Pharmaceutical Medicine in 2024 then our DPM Training Programme is designed to prepare you for success. Find out more at **fpm.org.uk/dpmtraining**

Are you ready to make a bigger impact on public health?

Professional ethics
Medical expertise
Standardised practice
Trustworth leadership

Four capabilities that make a difference in the world of pharmaceutical medicine. If you are looking to specialise in a field where the skill and experience acquired in your career to date changes lives at population level, pharmaceutical medicine is your next move. Make a bigger impact, enrol for PMST today.

Your route to professionalism in pharmaceutical medicine
fpm.org.uk/pmst

Faculty of
Pharmaceutical Medicine